(+)-Eburnamenine-14-carboxylic acid (2-nitroxyethyl) ester (VA-045), a putative cognitive enhancer, facilitates recovery from concussive brain injury-induced learning and memory impairments in mice.
We characterized alterations in the ability of concussive brain injury (CBI) models to perform a water-finding task and examined effects of (+)-eburnamenine-14-carboxylic acid (2-nitroxyethyl) ester (VA-045), a novel apovincaminic acid derivative, on post-traumatic impairments in latent learning and memory processes. Two types of CBI-induced amnesia (retrograde and anterograde) were produced by means of post- or preacquisition head impact using a simple weight-drop device. Profound impairments of latent learning and memory processes related to retention and retrieval were observed in the CBI mice. In the CBI-induced retrograde amnesia model, VA-045 (0.5-4.0 mg/kg) significantly ameliorated impairments of latent learning and retention in both the retention test and the retest. In the CBI-induced anterograde amnesia model, the protective effects of the compound on impairments in latent learning and retention or retrieval were significant in both the retention test and the retest. These results suggested that VA-045 may be a novel cognitive enhancer for attenuating or protecting against the learning and memory dysfunction associated with CBI.
Tang
Y P
YP
Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University School of Medicine, Japan.
Noda
Y
Y
Hasegawa
T
T
Nabeshima
T
T
D000648:Amnesia, Retrograde / Q000188:drug therapy / Q000523:psychology; D000818:Animals; D001924:Brain Concussion / Q000150:complications / Q000523:psychology*; D004327:Drinking Behavior / Q000187:drug effects; D005106:Exploratory Behavior / Q000187:drug effects; D007859:Learning Disabilities / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology; D008297:Male; D008569:Memory Disorders / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology; D051379:Mice; D008815:Mice, Inbred Strains; D018697:Nootropic Agents / Q000627:therapeutic use*; D014748:Vinca Alkaloids / Q000627:therapeutic use*
D018697:Nootropic Agents; D014748:Vinca Alkaloids; C081044:2-(nitrooxy)ethyl apovincaminate